Hepalink (Hong Kong) Limited announced that it will receive $20 million in an equity round of funding from returning investor Shenzhen Hepalink Pharmaceutical Co., Ltd. on January 23, 2016. Post transaction, the investor will maintain its stake at 100% in the company. The transaction was approved at the 19th meeting of the 3rd directorate and 14th meeting of the 3rd supervisory board of the investor.